Trial Profile
The Toca 7 Study: A Phase 1b Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 01 Apr 2020
Price :
$35
*
At a glance
- Drugs Vocimagene amiretrorepvec-flucytosine gene therapy (Primary) ; Temozolomide
- Indications Glioma
- Focus Adverse reactions
- Acronyms Toca7
- Sponsors Tocagen
- 26 Mar 2020 Planned initiation date changed from 1 Mar 2016 to 1 Jan 2017.
- 26 Mar 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 09 Aug 2017 According to a Tocagen media release, the company is planning to start this trial in the first half of 2018.